OOIR: Observatory of International Research

Papers

(The median citation count of ESC Heart Failure is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Corrigendum	93
	70
Characteristics and management of very elderly patients with heart failure: a retrospective, population cohort study	69
Right ventricular strain predicts outcome in patients receiving sacubitril/valsartan: A sub‐analysis of DISCOVER‐ARNI	67
Assessing the link of malnutrition with diabetes and mortality risk in heart failure patients	66
Explainable machine learning and online calculators to predict heart failure mortality in intensive care units	64
Use of liver stiffness measurements in acute decompensated heart failure: new applications of a non‐invasive technique	63
Calcium channel blockers and clinical outcomes in patients with continuous‐flow left ventricular assist devices	62
Prediction of cardiac events with non‐contrast magnetic resonance feature tracking in patients with ischaemic cardiomyopathy	62
Establishing a novel model to assess exercise capacity in chronic heart failure based on stress echocardiography	56
Synchronized diaphragmatic stimulation: a case report of a novel extra‐cardiac intervention for chronic heart failure	55
Different activation of MAPKs and Akt/GSK3β after preload vs. afterload elevation	55
Systolic dysfunction and mortality in critically ill patients: more data are needed to believe in this association!	54
Left atrial unloading with an 8 mm septal cutting balloon to treat postcapillary pulmonary hypertension: a case report	49
Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan	45
Cardiac involvement in patients recovering from Delta Variant of COVID‐19: a prospective multi‐parametric MRI study	44
New insight: particle flow rate from the airways as an indicator of cardiac failure in the intensive care unit	43
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry	42
Atrial fibrillation ablation in patients with arrhythmia‐induced cardiomyopathy: a prospective multicentre study	41
Impact of age on characteristics, performance measures and outcomes of inpatients for heart failure in Beijing, China	41
Serum angiotensin‐converting enzyme levels indicating early sarcoidosis diagnosis and immunosuppressive therapy efficacy	39
Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction	39
Discordance between estimated and measured changes in plasma volume among patients with acute heart failure	39
The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation	39
Fibroblast growth factor 23 independently predicts adverse outcomes after an acute coronary syndrome	39

Real‐time pulmonary artery pressure monitoring in heart failure patients: an updated cost‐effectiveness analysis	38
Burden of hospitalizations in newly diagnosed heart failure patients in Poland: real world population based study in years 2013–2019	38
Issue Information	38
Integrated care for older multimorbid heart failure patients: protocol for the ESCAPE randomized trial and cohort study	38
Cardiogenic shock requiring VA‐ECMO therapy in scorpionism‐induced myocarditis	37
Sex differences in the impact of frailty on patients with heart failure: A retrospective cohort study	37
Prognostic value of left atrial strain in acute and chronic heart failure: A meta‐analysis	37
Circ_0001206 regulates miR‐665/CRKL axis to alleviate hypoxia/reoxygenation‐induced cardiomyocyte injury in myocardial infarction	37
Effect of beta‐blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta‐analysis	37
Intense optimization of oral therapy rapidly restores respiratory function in worsening heart failure patients	37
Increased acylcarnitines in infant heart failure indicate fatty acid oxidation inhibition: towards therapeutic options?	36
Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine	36
Uncovering the genetic links of SARS‐CoV‐2 infections on heart failure co‐morbidity by a systems biology approach	36
Predictive value of global longitudinal strain by left ventricular ejection fraction	35
Reductions in renin‐angiotensin system inhibitors following hospitalization for heart failure	34
Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance	34
Blood perfusion status is important in the prognosis of ventricular aneurysm complicated by ventricular septal rupture	33
Global differences in acute heart failure treatment: analysis of the STRONG‐HF site feasibility questionnaire	33
Systemic immune‐inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction	33
Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST‐CHF study	32
Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta‐analysis	32
Acylation‐stimulating protein and heart failure progression in arrhythmogenic right ventricular cardiomyopathy	32
Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices	32
Editors' highlight picks from 2023 in ESC heart failure	32
Long‐term outcomes of electrical storm patients listed for urgent heart transplantation but not transplanted acutely	31
	31
Risk classification for long‐term mortality among patients with acute heart failure: China PEACE 4YMortality	31
Health‐related quality of life among transthyretin amyloid cardiomyopathy patients	30
Meta‐Analysis Global Group in Chronic Heart Failure score for the prediction of mortality in valvular heart disease	30
Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator	30
Meta‐analysis of cardiac magnetic resonance in prognosticating left ventricular function in peripartum cardiomyopathy	30
Oral iron supplementation in patients with heart failure: a systematic review and meta‐analysis	30
Prognostic value of hypoxaemic burden from overnight oximetry in heart failure with preserved ejection fraction	30
Early achievement of walkability after cardiac surgery and the risk of cardiovascular disease after hospital discharge	30
Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care	29
Clinical characteristics of people with heart failure in Australian general practice: results from a retrospective cohort study	29
Soluble neprilysin and survival in critically ill patients	29
Higher BNP/NT‐pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta‐analysis	29
Heart failure and trimethylamine N‐oxide: time to transform a ‘gut feeling’ in a fact?	29
Analysis of the serum levels of RIP3 and Drp1 in patients with heart failure	29
Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM	28
Identification of molecular signatures in epicardial adipose tissue in heart failure with preserved ejection fraction	28
Issue Information	28
Time‐domain heart rate variability features for automatic congestive heart failure prediction	28
Angiographic classification of total occlusion and its implication on balloon pulmonary angioplasty	28
Increasing home‐time after a first diagnosis of heart failure in Sweden, 20 years trends	28
Long‐term mortality in heart failure with mid‐range ejection fraction: systematic review and meta‐analysis	27
Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017	27
Left ventricular reverse remodelling as a promising strategy for resolving left ventricular thrombus	27
Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction	27

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator	27
Outcomes after heart transplantation in patients with cardiac sarcoidosis	27
Prognostic value of left atrial reverse remodelling in patients hospitalized with acute decompensated heart failure	27
Platelet count in heart failure patients undergoing left ventricular assist device	27
Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis	26
SARS‐CoV‐2‐related Multisystem Inflammatory Syndrome in Adult complicated by myocarditis and cardiogenic shock	26
Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease	26
Sex‐specific associations of cardiorespiratory fitness and galectin‐3 in the general population	26
Correction to “Understanding the variability in red cell and plasma volume combinations can help guide management in heart failure”	26
Letter to the editor regarding ‘Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis’	26
Delay in cardiology consultation after primary care physician referrals in heart failure: Clinical implications	25
Acute myocarditis according to age: Presentation, management and early outcomes	25
Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey	25
Transthyretin amyloid cardiomyopathy in aortic stenosis patients scheduled for transcatheter aortic valve implantation	25
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross‐over trial	25
Cost‐utility analysis of add‐on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China	25
Effects of homoarginine supplementation on heart and skeletal muscle of rats with heart failure with preserved ejection fraction	24
Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study	24
Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery	24
Performance of non‐invasive myocardial work to predict the first hospitalization for de novo heart failure with preserved ejection fraction	23
Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation	23
Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction	23
Effects of exercise modalities on physical function and quality of life in patients with heart failure: A systematic review and network meta‐analysis	23
A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting	23
Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction	22
Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure	22
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial	22
Takotsubo cardiomyopathy during armed conflict: A case series	22
Nutritional status during hospitalization is associated with the long‐term prognosis of patients with heart failure	22
Adaptive versus maladaptive right ventricular remodelling	22
Advances in device‐based treatment of heart failure with preserved ejection fraction: evidence from clinical trials	22
Clinical impact of follow‐up endomyocardial biopsy in myocarditis during or after immune‐suppressive therapy	22
Human epididymis protein 4 is a useful predictor of post‐operative prognosis in patients with severe aortic stenosis	22
Congestion, decongestion, renal function and diuretics in (ESC) heart failure	21
Determinants of left ventricular function improvement for cardiac resynchronization therapy candidates	21
Gender‐specific prevalence and trend of heart failure in China from 1990 to 2019	21
Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. A clinical consensus statement from the ESC Council for Cardiology Practice/Taskforce on Ger	21
Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode	21
Importance of non‐cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction	21
Simultaneous vaccination against influenza and respiratory syncytial virus in high‐risk heart failure patients	21
Changes over time in patient‐reported outcomes in patients with heart failure	20
A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure	20
Severe aortic insufficiency‐induced cardiogenic shock treated with left atrial VA‐ECMO and emergent valve‐in‐valve TAVR	20
Considerations for drug trials in hypertrophic cardiomyopathy	20
E prostanoid receptor‐3 promotes oxidized low‐density lipoprotein‐induced human aortic smooth muscle cells inflammation	20
Sex‐based differences in referral of heart failure patients to outpatient clinics: a scoping review	20
Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction	20
The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta‐analysis	20
Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair	20
Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study	19
Temporal profiling of M‐TEER‐related complications	19
Clinical performance and quality measures for heart failure management in China: the China‐Heart Failure registry study	19
Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction	19
Response to Letter to the editor regarding ‘Discordance between estimated and measured changes in plasma volume among patients with acute heart failure’	19
Prognostic impact of a history of cancer and atrial fibrillation in antithrombotic therapy for chronic heart failure	19
Prognostic impact of heart failure admission in survivors of acute myocardial infarction	19
The characteristic large‐scale annual analysis by gender and age in heart failure patients: cohort for 10 years in Korea	19
Biomarkers in heart failure: Traditional and emerging indicators for prognosis	19
Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography	19
Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single‐centre experience	19
Letter regarding the article “Hypocapnia is an independent predictor of in‐hospital mortality in acute heart failure”	19
Diabetes and treatment of chronic heart failure in a large real‐world heart failure population	19
Adequate immune response after SARS‐CoV‐2 infection and single dose vaccination despite rapid heart transplantation	19
Cognitive transitions based on functional status in older adults with heart failure: a population‐based study	19
Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review	19
Cardiovascular vs. non‐cardiovascular deaths after heart failure hospitalization in young, older, and very old patients	19
Tyrosine to threonine ratio was related to heart failure with reduced or mildly reduced ejection fraction	19
Corrigendum	19
Impact of B‐lines‐guided intensive heart failure management on outcome of discharged heart failure patients with residual B‐lines	19
Novel electrocardiographic criteria may render possible the more accurate recognition of cardiac amyloidosis	18
Clinical application and immune infiltration landscape of stemness‐related genes in heart failure	18
Association of iron deficiency with incident cardiovascular diseases and mortality in the general population	18
Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort	18
A contemporary simple risk score for prediction of severe acute kidney injury after heart transplantation	18
Smartwatches in the assessment of heart failure patients in epidemiology and pathophysiology studies: A scoping review	18
Novel mutation associated with non‐compaction ventricular myocardium: A case report	18
Novel active fixation lead guided by electrical delay can improve response to cardiac resynchronization therapy in heart failure	18
Biomarker prognostication across Universal Definition of Heart Failure stages	18
Pre‐emptive treatment of heart failure exacerbations in patients managed with the HeartLogic™ algorithm	18
Investigating the relationship between FRailty And Quality of LIfe in patients with heart faiLure and CKD (FRAIL study)	18

A meta‐analysis of the relationship between glycaemic variability and the mortality of patients with heart failure	18
Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure	18
Incidence, mortality, and predictors of acute kidney injury in patients with heart failure: a systematic review	18
Genotype is associated with left ventricular reverse remodelling and early events in recent‐onset dilated cardiomyopathy	18
Efficacy and safety of digital therapeutics‐based cardiac rehabilitation in heart failure patients: a systematic review	18
Narrative synthesis of the effectiveness and characteristics of heart failure disease self‐management support programmes	18
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study	18
A nationwide study of temporal trends of cause‐specific hospital readmissions in patients with heart failure	17
S₂I₂N_0–3 score predicts short‐ and long‐term mortality and morbidity in HFrEF: a post‐hoc analysis of the GUIDE‐IT trial	17
Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients	17
The efficacy and safety of sodium‐glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure	17
Correction to: “Obesity and contraceptive use: impact on cardiovascular risk”	17
Low‐density lipoprotein cholesterol, erythrocyte, and platelet in heart failure with preserved ejection fraction	17
Effects of bariatric surgery on cardiovascular‐related acute care use in patients with hypertrophic cardiomyopathy	17
Letter to the editor regarding ‘Discordance between estimated and measured changes in plasma volume among patients with acute heart failure’	17
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial	17
IgM‐enriched immunoglobulin as adjuvant therapy for heart transplant after infection of left ventricular assist devices	17
Newly diagnosed atrial fibrillation and hospital utilization in heart failure: a nationwide cohort study	17
Impact of the COVID‐19 pandemic on management and outcomes of patients with acute heart failure	17
Impact of cardiac resynchronization therapy optimization inside a heart failure programme: a real‐world experience	17
Sodium‐glucose transporter 2 inhibitors may improve the prognosis of acute heart failure by correcting hypocapnia	17
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis	17
Is ischaemic heart failure an autoimmune disease?	16
Utilizing longitudinal data in assessing all‐cause mortality in patients hospitalized with heart failure	16
Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF	16
Paediatric heart transplantation during the COVID‐19 pandemic in Iran: single‐centre experience	16
Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure	16
Safety and efficacy of MitraClip in acutely ill (NYHA Class IV) patients with mitral regurgitation: Results from the global EXPAND study	16
Coronary angiography in patients with acute heart failure: from the KCHF registry	16
Interpretation of elevated baseline concentrations and serial changes of high‐sensitivity cardiac troponin T in confirmed muscular dystrophies	16
Relationship between haemodynamic indicators and haemogram in patients with heart failure	16
Eniluracil blocks AREG signalling‐induced pro‐inflammatory fibroblasts of melanoma in heart failure	16
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence	16
The association between cardiac involvement and long‐term clinical outcomes in patients with Duchenne muscular dystrophy	16
Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides	16
Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?	16
Multiorgan characterization of inflammasome component expression in a rat model of advanced heart failure	15
Diuretic dose is a strong prognostic factor in ambulatory patients awaiting heart transplantation	15
Prognostic implications of functional tricuspid regurgitation in asymptomatic degenerative mitral regurgitation	15
Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre	15
Issue Information	15
Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters	15
Fractional excretion of urea nitrogen can identify true worsening renal function in patients with heart failure	15
Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure	15
Non‐dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes	15
Susceptibility to infections and adaptive immunity in adults with heart failure	15
Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events	15
Effect of early intervention on short‐term prognosis of patients with myocardial injury induced by acute carbon monoxide poisoning	15
Issue Information	15
Issue Information	15
Estimated pulse wave velocity and risk of new‐onset heart failure	15
Relationship of atrial fibrillation and N terminal pro brain natriuretic peptide in heart failure patients	15
Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure	15
Atrial‐secondary tricuspid regurgitation: a better prognosis in early stage heart failure, but not in late stage	15
Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure	15
Trametinib alters contractility of paediatric Noonan syndrome‐associated hypertrophic myocardial tissue slices	15
Integrin beta‐like 1 is regulated by DNA methylation and increased in heart failure patients	15
Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry	15
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care	15
The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles	15
Characterization of critically ill patients with septic shock and sepsis‐associated cardiomyopathy using cardiovascular MRI	15
Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy	15
Association of hypoxic burden metrics with cardiovascular outcomes in heart failure and sleep‐disordered breathing	14
Correction to “Impact analysis of heart failure across European countries: an ESC‐HFA position paper” and “Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory he	14
A case of biopsy‐proven inflammatory dilated cardiomyopathy following heterologous mRNA‐1273 third‐dose immunization	14
Short‐term outcomes after sodium‐glucose cotransporter‐2 inhibitor initiation in a cohort of heart failure patients	14
Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry	14
Dapagliflozin treatment and cardiovascular outcome in RBP4/TTR^Val30Met (transthyretin cardiac amyloidosis) mice	14
Decreased endogenous nitric oxide production in acute decompensated heart failure with a reduced ejection fraction	14
Immune Checkpoint Inhibitors and Cardiovascular Adverse Events	14
Construction of a web‐based dynamic nomogram for predicting the prognosis in acute heart failure	14
Role of depressive symptoms in the prognosis of heart failure and its potential clinical predictors	14
Right ventricular function and its coupling to pulmonary circulation predicts exercise tolerance in systolic heart failure	14
Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy	14
The favourable alliance between CardioMEMS and levosimendan in patients with advanced heart failure	14
ST‐segment depression and left ventricular systolic function recovery post‐atrial fibrillation ablation in heart failure	14
Associations between in‐hospital daily protein intake and adverse clinical outcomes in older patients with heart failure	14
Efficacy of catheter ablation for atrial fibrillation in heart failure: a meta‐analysis of randomized controlled trials	14
Association between central haemodynamics and renal function in advanced heart failure: a nationwide study from Sweden	14
Safety and efficacy of up to 60 h of iv istaroxime in pre‐cardiogenic shock patients: Design of the SEISMiC trial	14
Assessment of frailty in patients with heart failure: A new Heart Failure Frailty Score developed by Delphi consensus	14
Pressure–strain loops unveil haemodynamics behind mechanical circulatory support systems	14
Multidisciplinary care: A missing solution to SGLT2 inhibitor underuse in heart failure	14
Cardiac arrest caused by coronary occlusion during transcatheter aortic valve implantation: a unique cause	14
Application of recommended therapies among patients with heart failure during the Syrian conflict: reality and barriers	14
Transition from asymptomatic to symptomatic systolic chronic heart failure: rationale and design of TransitionCHF	14
Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction	14
A scoring evaluation for the practical introduction of guideline‐directed medical therapy in heart failure patients	14
Prognostic effect of systematic geriatric assessment on patients with acute heart failure	14
Neutrophil‐to‐lymphocyte ratio: link to congestion, inflammation, and mortality in outpatients with heart failure	14
Frailty alone and interactively with obesity predicts heart failure: Kuopio Ischaemic Heart Disease Risk Factor Study	14
Predicting 1‐year heart failure hospitalization and mortality post‐discharge from the intensive cardiac care unit	14
Two‐year outcome of ventricular assist device via a modified left atrium to aorta approach in cardiac amyloidosis	14
Pre‐admission beta‐blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock‐2 Registry	14
Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants	14